M., Nawoot, S., and Gerber, N
Zhang, Y.-G., Guo, X., Xu, P., Kang, L.-L
Products like ColonBroom GLP-1 Booster contain plant-based compounds that researchers have studied in metabolic contextsbut these represent a fundamentally different category with different mechanisms, regulatory frameworks, and evidence standards
A randomised controlled trial published in Diabetes Care reported that co-administration of probiotics with GLP-1 therapy resulted in significant improvements in fasting glucose levels and cholesterol profiles, suggesting an additive effect on metabolic parameters
RNA-seq data used in this study have been previously published and are available in our earlier publication [4]
At the opening of the 2023 annual meeting of the American Heart Association in Philadelphia, results of a clinical trial generated tremendous interest: Semaglutide, it appeared, was a new tool to treat heart disease